FK778, a synthetic malononitrilamide

Area of Science:

• Immunology
• Pharmacology
• Virology

Background:

• FK778 is a synthetic malononitrilamide (MNA) with demonstrated immunosuppressive and anti-proliferative properties.
• MNAs target de novo pyrimidine synthesis by inhibiting dihydroorotic acid dehydrogenase (DHODH) and tyrosine kinase activity.
• These mechanisms impact T-cell and B-cell function.

Purpose of the Study:

• To evaluate the efficacy of FK778 in preventing allograft rejection.
• To investigate FK778's role in preventing vascular remodeling.
• To assess FK778's antiviral activity against herpes viruses.

Main Methods:

• Experimental transplant models in rodents, dogs, and primates were used to assess FK778's efficacy in preventing acute and chronic allograft rejection.
• Mechanical intimal injury models were employed to study vascular remodeling.
• In vitro studies were conducted to evaluate antiviral activity against cytomegalovirus (CMV) and polyoma virus.

Main Results:

• FK778 successfully prevented acute allograft rejection in multiple animal models.
• The compound was effective in a rat model of chronic renal allograft rejection.
• FK778 demonstrated efficacy in preventing vascular remodeling and showed in vitro activity against CMV and polyoma virus.

Conclusions:

• FK778 exhibits significant potential as an immunosuppressant to prevent organ transplant rejection.
• Its dual mechanism, involving DHODH and tyrosine kinase inhibition, contributes to its broad therapeutic effects.
• FK778's antiviral properties and efficacy in preventing vascular remodeling warrant further investigation for transplant recipients.